SCHEMBL3317020

SCHEMBL3317020

O=C(O)N1CC(N2C(=O)c3ccc(F)cc3C2=O)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
HTT P42858 1/20 0.41
KMT2A Q03164 3/20 0.40
TSHR P16473 2/20 0.40
ALDH1A1 P00352 6/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
ATM Q13315 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MAPK1 P28482 2/20 0.39
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6430645 0.81 L3MBTL1 (0.49) DDB1CRBNKMT2ATSHRALDH1A1
SCHEMBL1957846 0.74 CA1 (0.44) DDB1CRBNKMT2AALDH1A1KDM4E
SCHEMBL25284676 0.71 L3MBTL1 (0.43) DDB1CRBNKMT2ATSHRALDH1A1
SCHEMBL25269554 0.71 L3MBTL1 (0.43) DDB1CRBNKMT2ATSHRALDH1A1
SCHEMBL28261071 0.70 AVPR2 (0.44) ALDH1A1KDM4EGAAMAPT
SCHEMBL31259851 0.70 HTR2A (0.48) DDB1CRBNKMT2ATSHRALDH1A1
SCHEMBL25277410 0.69 HTR2B (0.55) DDB1CRBNKMT2ATSHRALDH1A1
SCHEMBL24309093 0.69 CRBN (0.60) DDB1CRBNHTTKMT2ATSHR
SCHEMBL16337692 0.68 BTK (0.46) CRBNHTTNPC1MAPT
SCHEMBL860585 0.68 MC4R (0.38) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105651-A1 ANTAGONISTS OF SNS SODIUM CHANNELS VERNALIS (R&D) LIMITED (GB) 2010-04-29 US disclosed
EP-1933830-A1 ANTAGONISTS OF SNS SODIUM CHANNELS Vernalis (R&D) Limited (GB) 2008-06-25 EP disclosed
WO-2007007057-A1 ANTAGONISTS OF SNS SODIUM CHANNELS VERNALIS (R & D) LIMITED (GB) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105651-A1 ANTAGONISTS OF SNS SODIUM CHANNELS CNR1, OPRL1, CHRNA10 DDB1 3575/4885CRBN 1597/4885HTT 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.